NewEdge Wealth LLC Boosts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

NewEdge Wealth LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 122.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 6,597 shares of the company’s stock after buying an additional 3,629 shares during the quarter. NewEdge Wealth LLC’s holdings in IDEXX Laboratories were worth $4,463,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of IDXX. EverSource Wealth Advisors LLC grew its stake in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after buying an additional 15 shares in the last quarter. CWA Asset Management Group LLC grew its stake in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after buying an additional 17 shares in the last quarter. Stratos Wealth Partners LTD. grew its stake in IDEXX Laboratories by 1.7% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after buying an additional 18 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in IDEXX Laboratories by 11.5% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after buying an additional 18 shares in the last quarter. Finally, Rockland Trust Co. grew its stake in IDEXX Laboratories by 4.4% in the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock valued at $288,000 after buying an additional 18 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 2,693 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the transaction, the executive vice president owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. The trade was a 11.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 34,612 shares of company stock valued at $22,525,070 in the last ninety days. Corporate insiders own 0.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of IDEXX Laboratories in a research note on Monday, April 27th. BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Barclays reduced their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $532.00 on Tuesday. The company has a 50 day moving average of $581.15 and a 200 day moving average of $648.62. The stock has a market cap of $41.96 billion, a P/E ratio of 39.18, a P/E/G ratio of 3.26 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12 month low of $496.61 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.65 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.